Clinical Trials Logo

Other clinical trials

View clinical trials related to Other.

Filter by:

NCT ID: NCT05340985 Not yet recruiting - Clinical trials for Multiple Sclerosis, Relapsing-Remitting

Investigating the Effects of Hydroxyvitamin D3 on Multiple Sclerosis

Start date: July 2022
Phase: Phase 4
Study type: Interventional

Investigating the effects of hydroxyvitamin D3 on clinical, radiologic and immunomodulatory markers in MS patients: A randomized, clinical trial- a pilot study

NCT ID: NCT05339854 Not yet recruiting - Clinical trials for Myocardial Infarction

Evaluation of eCPR Survivors

Start date: June 1, 2023
Phase:
Study type: Observational

A cardiac arrest event has severe impact on the patient´s health-related quality of life. Survival of cardiac arrest does not innately translate to favorable quality of life. In particular, highly invasive resuscitation strategies, including extracorporeal cardio-pulmonary resuscitation (ECPR) due to therapy-refractory cardiac arrest, may have impact on long-term outcomes. Therefore, apart from acute medical treatment and physical rehabilitation, long-term effects on cardio-pulmonary, physical and neuro-psychiatric functions after cardiac arrest survival have to be evaluated and optimized. We plan to investigate a bundle of cardio-pulmonary, physical and neuro-psychiatric functions in patients who survived a therapy-refratory cardiac arrest with ECPR.

NCT ID: NCT05337241 Not yet recruiting - Clinical trials for Refractory Ventricular Tachycardia

Saline Enhanced Radiofrequency (SERF) Needle Ablation for Refractory VT

Start date: November 1, 2022
Phase: N/A
Study type: Interventional

The Thermedical Ablation System and Durablate catheter is indicated for use in patients with recurrent, sustained, monomorphic ventricular tachycardia (SMVT) refractory to drug therapy and conventional (approved) catheter ablation. Subjects with recurrent, SMVT refractory to drug therapy and conventional catheter ablation who are not eligible for, or will not likely benefit from repeat endocardial ablation using an approved catheter.

NCT ID: NCT05335512 Not yet recruiting - Clinical trials for Non-Invasive Bladder Urothelial Carcinoma

Intravesical BCG: is the Urinary Bladder Ready to Receive it

Start date: September 1, 2022
Phase:
Study type: Observational

Prospective cohort and Prospective observational study which aims To define the healing time-frame of the resected area of the bladder after TURBT. and also to validate a grading system of healing of the bladder mucosa after TURBT. To assess the factors influencing bladder healing is also one of the secondary objectives.

NCT ID: NCT05331001 Not yet recruiting - Clinical trials for Myocardial Infarction

Quality of Care in Centers Providing Extracorporeal Membrane Oxygenation

Start date: June 1, 2022
Phase:
Study type: Observational [Patient Registry]

Cardiac arrest centers are specialized in treating critically ill patients with severe cardiovascular diseases, such as cardiac arrest, cardiogenic shock or acute myocardial infarction. Diagnostic and therapeutic measures, such as the use of devices for extracorporeal life support, require highly specialized training and skills. Apart from extensive medical expertise, physicians and nurses may be exposed to exceptional levels of occupational stressors. Therefore, excellent medical, psychological and inter-personal training of the medical staff is essential to improve patient outcomes. Assessment of quality of care is important to provide continuous improvement in patient care and team performance. To the best of our knowledge, there is no study which examined the quality of care in cardiac arrest centers across key dimensions of quality of care. Therefore, we aim to assess a bundle of key dimensions, that is psychological strain (P), resource utilization (R), interaction (I) between doctoral and nursing staff, costs of care (C) and education (E) programs for staff (PRICE scheme). A cross-sectional study will be conducted with doctors and nurses, using a digital quesitonnaire that will cover the five dimensions of the PRICE scheme.

NCT ID: NCT05330182 Not yet recruiting - Clinical trials for Clostridioides Difficile Infection

LMN-201 for Prevention of C. Difficile Infection Recurrence

Start date: August 19, 2024
Phase: Phase 2/Phase 3
Study type: Interventional

This is a multisite study to evaluate the safety, tolerability, and efficacy of LMN-201 in participants recently diagnosed with CDI who are scheduled to receive or are receiving SOC antibiotic therapy against C. difficile.

NCT ID: NCT05328817 Not yet recruiting - Clinical trials for Preterm Premature Rupture of Membrane

Azithromycin Versus Erythromycin For Preterm Prelabor Rupture of Membranes

Start date: May 1, 2022
Phase: N/A
Study type: Interventional

Aim 1. To examine the latency period according to antibiotic regimens (erythromycin iv for two days followed by orally for 5 days vs. azithromycin iv for 2 days followed by 5 days orally). Aim 2. To examine the latency period according to races stratified by antibiotic regimens. Aim 3: To examine if there is a difference in neonatal morbidity and mortality stratified by antibiotic regimen.

NCT ID: NCT05327673 Not yet recruiting - Clinical trials for Allogeneic Hematopoietic Stem Cell Transplantation

Impact of the Use of Allogeneic Hematopoietic Stem Cell Transplantation in Reunion Island Patients: Quality of Life, Determinants of Choices and Financial Repercussions

AlloRé
Start date: July 2022
Phase:
Study type: Observational

This project aims to document and analyse - with a three-fold anthropological, psychosocial and economical approach - the consequences of the geographical distance from mainland France on the alloSCT on both patients, their caregivers and the healthcare system. It is organised in 3 working packages (WP).

NCT ID: NCT05326087 Not yet recruiting - Clinical trials for Polycystic Ovarian Syndrome

Comparison of the Euploid Rate of Blastocyst Between PPOS and GnRH Antagonist Protocol in Women With PCOS Undergoing PGT-A

Start date: December 1, 2024
Phase: Phase 3
Study type: Interventional

This randomized trial aims to compare the euploid rate of blastocysts between PPOS (progestin-primed ovarian stimulation) and GnRH (gonadotrophin releasing hormone) antagonist protocols in patients with PCOS (polycystic ovary syndrome) undergoing PGT-A (preimplantation genetic testing for aneuploidy). Infertile women with PCOS will be recruited for study after explanation and counseling if they fulfill the inclusion criteria and do not have the exclusion criteria. Eligible women will be randomised into one of the two groups: Antagonist group: Women will receive antagonist once subcutaneously daily from day 6 of ovarian stimulation till the day of the ovulation trigger. PPOS group: Women will receive oral MPA (medroxyprogesterone acetate)10mg qd from Day 3 till the day of ovulation trigger. The primary outcome is the euploidy rate of blastocysts.

NCT ID: NCT05326035 Not yet recruiting - Clinical trials for Locally Advanced or Metastatic Malignant Solid Tumors

A Study of WJ05129 in Advanced Malignant Solid Tumors

Start date: April 30, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This study was an open, multicenter Phase I/II clinical study of WJ05129 in patients with locally advanced or metastatic malignant solid tumors in China, which was divided into three stages: dose escalation, dose extension and efficacy extension. The study included screening, treatment and follow-up periods. Dose escalation phase: adopt "3 + 3" dose escalation mode, preset 5 dose groups: 1.25mg, 2.5mg, 5mg, 7.5mg, 10mg, oral, twice a day (only once on the first day), planned to include a maximum of 30 subjects; Dose expansion phase: 2 dose groups will be planned in this phase, and the specific dose will be determined according to the trial data in the dose escalation phase. The maximum number of participants in each dose group will be 12. Efficacy expansion phase: It is preliminarily planned to expand three cohorts of Rb negative TNBC and SCLC and NB with high Myc expression, and recruit about 24 people in each cohort.